Abeona Therapeutics Inc. Common Stock (ABEO)
Stock · NASDAQ · Health Care
$4.44as of 10/16/2026
Price chart
Active signals
ABEO Signal Track Record
How signals performed across all stocks →What ABEO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 45 | -0.8% | 47% | September 9, 2026 |
| Bollinger Band Breakout | 21 | -4.2% | 48% | June 30, 2026 |
| Bollinger Band Breakdown | 18 | +9.7% | 72% | September 10, 2026 |
| 200-Day Moving Average TouchActive now | 16 | +5.5% | 63% | September 10, 2026 |
| Any 20-session window (baseline) | +0.4% | 51% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ABEO
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 226
- Website
- abeonatherapeutics.com/
Fundamentals
- 1-day range
- $4.39$4.66
- Market cap
- $393.27M
- P/E (trailing)
- 5.50
- P/E (forward)
- -21.35
- EPS (trailing)
- $-1.12
- Dividend yield
- —
- Beta
- 1.45
- Avg. volume
- 1.40M
How Abeona Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 17, 2026 · via SEC EDGAR / Finnhub
Forecasts
8 analyst ratings
Abeona Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ABEOAbeona Therapeutics Inc. Common Stock$4.43▼ 4.73%Market cap $393.27MP/E 5.50$4$7.65
- ENTAEnanta Pharmaceuticals Inc. Common Stock$11.1▼ 3.23%Market cap $387.91MP/E —$10.2$17.15
- AVIRAtea Pharmaceuticals Inc. Common Stock$4.32▼ 4.64%Market cap $399.34MP/E —$2.87$6.45
- RCKTRocket Pharmaceuticals Inc. Common Stock$2.18▼ 7.63%Market cap $386.55MP/E —$2.42$5.45
- KMDAKamada Ltd. Ordinary Shares$7.76▼ 0.89%Market cap $411.88MP/E 20.30$6.55$9.35
- UPBUpstream Bio Inc. Common Stock$2.76▼ 18.10%Market cap $373.87MP/E —$3.29$33.68
- PBYIPuma Biotechnology Inc Common Stock$9.83▼ 6.56%Market cap $413.30MP/E 20.62$4.58$10.5
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ABEO Abeona Therapeutics Inc. Common Stock | $393.27M | 5.50 | $4.43 | ▼ 4.73% | $4$7.65 |
| ENTA Enanta Pharmaceuticals Inc. Common Stock | $387.91M | — | $11.1 | ▼ 3.23% | $10.2$17.15 |
| AVIR Atea Pharmaceuticals Inc. Common Stock | $399.34M | — | $4.32 | ▼ 4.64% | $2.87$6.45 |
| RCKT Rocket Pharmaceuticals Inc. Common Stock | $386.55M | — | $2.18 | ▼ 7.63% | $2.42$5.45 |
| KMDA Kamada Ltd. Ordinary Shares | $411.88M | 20.30 | $7.76 | ▼ 0.89% | $6.55$9.35 |
| UPB Upstream Bio Inc. Common Stock | $373.87M | — | $2.76 | ▼ 18.10% | $3.29$33.68 |
| PBYI Puma Biotechnology Inc Common Stock | $413.30M | 20.62 | $9.83 | ▼ 6.56% | $4.58$10.5 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 10/2/2026
- Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. WainwrightYahoo · 9/22/2026
- Abeona Expands ZEVASKYN Network as RDEB Launch Gains MomentumYahoo · 9/22/2026
- Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)Yahoo · 9/18/2026
- Apple To Rally Around 13%? Here Are 10 Top Analyst Forecasts For FridayBenzinga · 9/18/2026
- Abeona Stands to Collect Royalties After Ultragenyx's FDA Approval — Here's the Rest of the WeekBenzinga · 9/18/2026
- Cantor Fitzgerald Maintains Overweight on Abeona Therapeutics, Raises Price Target to $30Benzinga · 9/18/2026
- ABEO Stock Gains On Approval For A Drug Abeona Sold, Rating For The One It SellsYahoo · 9/17/2026
Insider Activity
Insider Actions →- Brendan M. O'Malley · September 29, 2026 · Sale6.7K @ $5.16
- Vishwas Seshadri · September 29, 2026 · Sale19.6K @ $5.16
- Joseph Walter Vazzano · September 29, 2026 · Sale9.2K @ $5.16
- Madhav Vasanthavada · September 29, 2026 · Sale4.9K @ $5.16
- Mark Alvino · September 1, 2026 · Sale15.0K @ $5.86
- Joseph Walter Vazzano · July 21, 2026 · Sale1.5K @ $6.53
- Madhav Vasanthavada · July 9, 2026 · Sale12.6K @ $6.96
- Brendan M. O'Malley · July 9, 2026 · Sale12.1K @ $6.96
- Vishwas Seshadri · July 9, 2026 · Sale68.0K @ $6.96
- Joseph Walter Vazzano · July 9, 2026 · Sale24.9K @ $6.96
- Leila Alland · June 30, 2026 · Sale11.0K @ $5.92
- Christine Berni Silverstein · June 15, 2026 · Sale18.2K @ $5.71
- Madhav Vasanthavada · June 9, 2026 · Sale5.5K @ $5.3
- Brendan M. O'Malley · June 9, 2026 · Sale6.3K @ $5.3
- Vishwas Seshadri · June 9, 2026 · Sale31.9K @ $5.3
Institutional Ownership
March 31, 2026
- Total shares held
- 40.68M
- Total value held
- $182.02M
- Institutional holders
- 102
- Unknown6.03M
- Unknown3.20M
- Unknown3.10M
- Unknown3.01M
- Unknown2.68M
- Unknown2.16M
- Unknown1.33M
- Unknown1.26M
- Unknown1.21M
- Unknown1.13M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Abeona Reports ZEVASKYN Launch Momentum and Revenue Growth
Abeona Therapeutics highlighted positive momentum for its ZEVASKYN product launch and revenue growth during a recent H.C. Wainwright event. The company is also expanding its distribution network as the treatment for RDEB gains traction. These developments provide fundamental context for the stock, which is currently trading near its 52-week low.
Abeona Reports ZEVASKYN Launch Momentum and Revenue Growth. Abeona Therapeutics highlighted positive momentum for its ZEVASKYN product launch and revenue growth during a recent H.C. Wainwright event. The company is also expanding its distribution network as the treatment for RDEB gains traction. These developments provide fundamental context for the stock, which is currently trading near its 52-week low.